Requests similar to 'Cost of Effexor v's Enlafax'
Arrow Venlafaxine needs to come back under NZ funding.
Response by Pharmaceutical Management Agency to VICKI CAREY on .
Partially successful.
Kia ora Vicki
Thank you for your enquiry. You have asked why the Arrow-Venlafaxine XR
and Efexor XR brands were removed when it was doing good f...
Vanlafaxine - Bioavailability studies
Response by Pharmaceutical Management Agency to R Whyte on .
Awaiting classification.
Dear R Whyte
Please see attached the response to your OIA request.
Kind regards
Dean Zeng
PHARMAC
16 April 2018
Via Email: [e...
Dear Trudi
Thank you for your query regarding the initial listing date for
Arrow-Venlafaxine XR tablets in the Pharmaceutical Schedule.
Ar...
Dispensed drugs, media and events information request
Response by Pharmaceutical Management Agency to Joe Heihei on .
Awaiting classification.
Dear Joe
Please see attached the response to your OIA request.
Kind regards
Dean Zeng
PHARMAC
25 May 2018
Dear Joe
REQUEST FO...
Ministry of Health,
Medsafe
REF - H201803736
Thank you for your reply to my request for information under the OIA, made on the 8th May 2018. In...
Reply to Maima Koro re Request H201803736.
Follow up sent to Ministry of Health by Trudi Webber on .
Dear Mr James,
Thank you for your reply to my request for information under the OIA. In response to your reply I have have a few questions that I...
Who did the research that was used to compare Enlafax with other brands?
Response by Pharmaceutical Management Agency to Trudi Webber on .
Successful.
Hi Trudi
Please find attached PHARMAC’s respond to your recent OIA request.
Kind regards
Katie
PHARMAC
16 May 2018
Dear Ms Webber
REQ...
Trikafta "27 more years at full health" claim.
Response by Pharmaceutical Management Agency to Laydan Mortensen on .
Successful.
Kia ora Laydan
Please find attached a response to your request for official information.
Ngâ mihi,
Government Services | Pharmac
___________________...
Information regarding Dexcom CGMS and Libre FGMS
Response by Pharmaceutical Management Agency to D Smith on .
Awaiting classification.
Kia ora D Smith
Further to our previous email to you on Friday 19 March 2021, please find
attached the final response to your request for inform...
Kia ora,
Please see attached your response.
Arihia Gray [1](she/her) | Policy advisor
From:
Sent:
To:
Cc:
Subject:
Sarah Fitt
Friday,...
Cost of funding PrEP
Response by Pharmaceutical Management Agency to Felix Swadel on .
Awaiting classification.
Hi Felix
Please see attached the response to your OIA request.
Kind regards
Dean
PHARMAC
1 November 2018
Felix Swadel
Via email:...
All emails from the Chief Executive, Director of Operations and communications staff in 2022 mentioning continuous glucose monitors
Response by Pharmaceutical Management Agency to Stefan Clausing on .
Awaiting classification.
Kia ora Stefan,
Please find a response to your request attached to this email.
Kind regards,
Gendi McFadyen| Government Services Advisor
Te Pātaka W...
Wholesale cost of anti emetic medications.
Request sent to Pharmaceutical Management Agency by Gregory Soar on .
Successful.
I would like to know the annual total cost paid by Pharmac or authorised by Pharmac, using the latest year for which figures are available, for fund...
Discontinuation of Phenelzine Sulphare
Response by Pharmaceutical Management Agency to Megs on .
Successful.
Dear Megs
Attached is PHARMAC's response to your recent information request.
Kind regards
PHARMAC | Te Pātaka Whaioranga | PO Box 10 254 | Level 9,...
Decision to delay Pump and CGM Funding for T1 Diabetics
Response by David Seymour to Fiona Smith on .
Awaiting classification.
Dear Fiona
Please find attached response to your OIA request of 29 May.
Kind regards, Annette
Annette Gratkowski | Private Secretary...
Cost of PreP since funding began in 2018
Response by Pharmaceutical Management Agency to Elliot Ikilei on .
Successful.
Kia ora Elliot
Please find attached a response to your request for information received
by PHARMAC on 6 January 2021.
Please feel free to...
Which thyroid medications and bio-identical T4, T3 equivalents meet criteria for government funding
Response by Pharmaceutical Management Agency to Belinda Hodson on .
Successful.
Good morning Ms Hodson,
Please find attached PHARMAC’s response to your OIA request.
Kind regards
Alexis Poppelbaum
PHARMAC
28 August 2...
Official Information Act Request — Expenditure on The Pākehā Project
Response by Ministry of Business, Innovation & Employment to Liam Hehir on .
Awaiting classification.
Tēnā koe Liam
Please find attached the response to your OIA request to the Ministry of
Business, Innovation and Employment [ref: DOIa-REQ-000607...
Public knowledge of communication
Response by Pharmaceutical Management Agency to A L.C on .
Successful.
Kia ora
Please find attached a response to your request for official information.
Ngā mihi
Government Services | Pharmac
______...
Data about foreign born elderlies accessing Health benefit
Request sent to Ministry of Health by G Sharma on .
Information not held.
My request is in relation to the currently ongoing hearsays regarding "Immigrant parents" clogging up the hospitals where people have made a percept...
Remdesivir costs $4400 per person - Covid 19: European study finds no clinical benefit
Follow up sent to Pharmaceutical Management Agency by Micky Turner on .
Successful.
Hi Melody,
Thanks for providing the information!
Here is a summary of the details:
Remdesivir is a failed Ebola drug. It was designed to treat E...
Meeting notes and outcomes
Response by Pharmaceutical Management Agency to A L.C on .
Awaiting classification.
Kia ora AL.C,
Please find attached the final part of your response, to your Official
Information Act request.
Please contact us if you hav...
Project Propel / IGF
Response by New Zealand Trade and Enterprise to Sarah Hillsdene on .
Awaiting classification.
Hi Sarah,
Please find attached NZTE's response to your OIA request.
Many thanks,
Maya.
From: Ministerials <[NZTE request email]>
S...
Maori Advisory Committee
Response by Pharmaceutical Management Agency to Alan Riley on .
Successful.
Kia ora Alan,
Please find attached a response to your Official Information Act request,
which was received on 13 November 2024.
Please con...
The 2022 Therapeutic Products Bill
Response by Andrew Little to Tracy Livingston on .
Awaiting classification.
Kia ora Tracy,
Please find attached a response to your request for information.
Ngā mihi
OIA Services Team
Manatū Hauora | Ministry of Hea...
